

25 November 2010 EMA/HMPC/12402/2010 Committee on Herbal Medicinal Products (HMPC)

Community herbal monograph on *Juniperus communis* L., aetheroleum

Final

Discussion in Working Party on Community monographs and Community	January 2010	
list (MLWP)	March 2010	
Adoption by Committee on Herbal Medicinal Products (HMPC) for release	15 March 2010	
for consultation	13 Maich 2010	
End of consultation (deadline for comments). Comments should be	15 August 2010	
provided using this template to hmpc.secretariat@ema.europa.eu	15 August 2010	
Rediscussion in Working Party on Community monographs and	September 2010	
Community list (MLWP)	November 2010	
Adoption by Committee on Herbal Medicinal Products (HMPC)	25 November 2010	

Keywords	Herbal medicinal products; HMPC; Community herbal monographs; traditional
	use; Juniperus communis L., aetheroleum; Juniperi aetheroleum; juniper oil

BG (bălgarski): хвойна	LT (lietuvių kalba): kadagys
CS (čeština): jalovec	LV (latviešu valoda): kadiķis
DA (dansk): enebær	MT (malti):
DE (Deutsch): Wachholder	NL (nederlands): jeneverbes (vluchtige olie)
EL (elliniká):	PL (polski): jałowiec
EN (English): juniper (essential oil)	PT (português): junípero
ES (espanol): enebro	RO (română): ienupăr
ET (eesti keel): kadakas	SK (slovenčina): brinje
FI (suomi): kataja	SL (slovenščina): borievka
FR (français): genièvre (huile essentielle de)	SV (svenska): en
HU (magyar): boróka	IS (íslenska): einir
IT (italiano): ginepro	NO (norsk): einer



Community herbal monograph on *Juniperus communis* L., aetheroleum

1. Name of the medicinal product

To be specified for the individual finished product.

2. Qualitative and quantitative composition^{1, 2}

Well-established use	Traditional use
	With regard to the registration application of Article 16d(1) of Directive 2001/83/EC as amended
	Juniperus communis L., aetheroleum (juniper oil)
	i) Herbal substance Not applicable.
	ii) Herbal preparations Essential oil obtained by steam distillation from
	the ripe, non-fermented berry cones.

3. Pharmaceutical form

Well-established use	Traditional use
	Herbal preparation in liquid dosage forms for oral and cutaneous use.
	The pharmaceutical form should be described by the European Pharmacopoeia full standard term.

¹ The material complies with the Ph. Eur. monograph (ref.: 1/2008:1832).

² The declaration of the active substance(s) for an individual finished product should be in accordance with relevant herbal quality guidance.

4. Clinical particulars

4.1. Therapeutic indications

Well-established use	Traditional use
	Oral use
	Indication 1) Traditional herbal medicinal product to increase the amount of urine to achieve flushing of the urinary tract as an adjuvant in minor urinary tract complaints.
	Indication 2) Traditional herbal medicinal product for symptomatic relief of digestive disorders such as dyspepsia and flatulence.
	Cutaneous use
	Indication 3) Traditional herbal medicinal product as adjuvant in the relief of minor muscular and articular pain.
	The product is a traditional herbal medicinal product for use in specified indications exclusively based upon long-standing use.

4.2. Posology and method of administration

Well-established use	Traditional use
	Posology
	Oral use
	Adults and elderly
	Average daily dose
	60-100 mg juniper oil to be taken in 1-3 doses.
	The use in children and adolescents under 18 years of age is not recommended (see section 4.4 'Special warnings and precautions for use').
	Cutaneous use
	Adolescents, adults and elderly
	Bath additive 3-4 times weekly 1-1.5 g juniper oil in full bath for 10-20 minutes at 35-38°C.
	The use in children under 12 years of age is not recommended (see section 4.4 'Special warnings and precautions for use').

Well-established use	Traditional use
	Duration of use
	If symptoms persist longer than 2 weeks during the use of the medicinal product, a doctor or a qualified health care practitioner should be consulted.
	Method of administration
	Oral use.
	Cutaneous use.

4.3. Contraindications

Well-established use	Traditional use
	Hypersensitivity to the active substance. Indications 1) and 2) Severe renal disease including infectious interstitial nephritis, pyelitis and pyelonephritis. Indication 1)
	Conditions where reduced fluid intake is recommended (e.g. severe cardiac diseases).

4.4. Special warnings and precautions for use

Well-established use	Traditional use
	If the symptoms worsen during the use of the medicinal product, a doctor or a qualified health care practitioner should be consulted.
	Oral use
	The use in children and adolescents under 18 years of age has not been established due to lack of adequate data.
	Indication 1) Appropriate fluid intake is recommended.
	If complaints or symptoms such as fever, dysuria, spasms or blood in the urine occur during the use of the medicinal product, a doctor or a qualified health care professional should be consulted.
	The use of this product is not recommended in case of oedema due to limited heart and kidney function.
	Cutaneous use

Well-established use	Traditional use
	The use in children under 12 years of age has not been established due to lack of adequate data.
	In cases of hypertension, a full bath should be used with caution.

4.5. Interactions with other medicinal products and other forms of interaction

Well-established use	Traditional use
	None reported.

4.6. Pregnancy and lactation

Well-established use	Traditional use
	Safety during pregnancy and lactation has not been established. In the absence of sufficient data, the use during pregnancy and lactation is not recommended.

4.7. Effects on ability to drive and use machines

Well-established use	Traditional use
	No studies on the effect on the ability to drive and use machines have been performed.

4.8. Undesirable effects

Well-established use	Traditional use
	Allergic skin reactions have been reported. The frequency is not known.
	If other adverse reactions not mentioned above occur, a doctor or a qualified health care practitioner should be consulted.

4.9. Overdose

Well-established use	Traditional use
	In case of prolonged oral use and overdose, urine will smell of violets. There may be renal irritation and kidney pain, strong diuresis, albuminuria, haematuria, purplish urine, gastrointestinal upsets, increased heartbeat and blood pressure. Rarely symptoms of central stimulation like

Well-established use	Traditional use
	convulsions occur as well as metrorrhagia and abortion.

5. Pharmacological properties

5.1. Pharmacodynamic properties

Well-established use	Traditional use
	Not required as per Article 16c (1)(a)(iii) of Directive 2001/83/EC as amended.
	There is limited evidence from non-clinical studies that juniper may influence glucose levels in diabetes.

5.2. Pharmacokinetic properties

Well-established use	Traditional use
	Not required as per Article 16c (1)(a)(iii) of Directive 2001/83/EC as amended.

5.3. Preclinical safety data

Well-established use	Traditional use
	Not required as per Article 16c (1)(a)(iii) of Directive 2001/83/EC as amended, unless necessary for the safe use of the product. Adequate tests on reproductive toxicity, genotoxicity and carcinogenicity have not been performed.

6. Pharmaceutical particulars

Well-established use	Traditional use
	Not applicable.

7. Date of compilation/last revision

25 November 2010